Literature DB >> 11176377

Adequacy of a single stone risk analysis in the medical evaluation of urolithiasis.

C Y Pak1, R Peterson, J R Poindexter.   

Abstract

PURPOSE: We tested the hypothesis that a single 24-hour urine sample for stone risk analysis would be sufficient for the simplified medical evaluation of urolithiasis.
MATERIALS AND METHODS: We retrospectively analyzed stone risk profile data on 24-hour urine samples obtained during random and restricted diets in 225 patients with recurrent urolithiasis.
RESULTS: In 2 random samples we noted no significant difference in urinary calcium, oxalate, uric acid, citrate, pH, total volume, sodium, potassium, sulfate or phosphorus. For these risk factors there was a highly significant positive correlation in the 2 random samples (r > or = 0.68, p <0.0003) and the value of each was abnormal or normal in at least 81% of patients. Urinary magnesium and ammonium were significantly lower in random sample 2 than 1, the former by 4%. After calcium, sodium and oxalate dietary restriction mean urinary calcium and sodium plus or minus standard deviation decreased significantly by 25% from 251 +/- 125 to 187 +/- 98 mg. daily and by 38% from 183 +/- 87 to 113 +/- 57 mEq. daily, respectively. Other risk factors had a slight or no significant change. Correcting random urinary calcium for the excessive urinary excretion of sodium brought urinary calcium to 210 +/- 108 mg. daily, similar to the value on the restricted diet.
CONCLUSIONS: The reproducibility of urinary stone risk factors is satisfactory in repeat urine samples. A single stone risk analysis is sufficient for the simplified medical evaluation of urolithiasis.

Entities:  

Keywords:  Non-programmatic

Mesh:

Year:  2001        PMID: 11176377     DOI: 10.1097/00005392-200102000-00006

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

1.  Variations between two 24-hour urine collections in patients presenting to a tertiary stone clinic.

Authors:  Madhur Nayan; Mohamed A Elkoushy; Sero Andonian
Journal:  Can Urol Assoc J       Date:  2012-02       Impact factor: 1.862

2.  Evaluation and medical management of the kidney stone patient.

Authors:  Ryan Paterson; Alfonso Fernandez; Hassan Razvi; Roger Sutton
Journal:  Can Urol Assoc J       Date:  2010-12       Impact factor: 1.862

3.  Update on the evaluation of repeated stone formers.

Authors:  Adam O Kadlec; Thomas M Turk
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

4.  Medical evaluation and management of urolithiasis.

Authors:  Michelle Jo Semins; Brian R Matlaga
Journal:  Ther Adv Urol       Date:  2010-02

5.  CUA guideline on the evaluation and medical management of the kidney stone patient - 2016 update.

Authors:  Marie Dion; Ghada Ankawi; Ben Chew; Ryan Paterson; Nabil Sultan; Patti Hoddinott; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2016-11-10       Impact factor: 1.862

6.  Preservation of urine samples for metabolic evaluation of stone-forming patients.

Authors:  Renato Ribeiro Nogueira Ferraz; Alessandra Calábria Baxmann; Larissa Gorayb Ferreira; José Luiz Nishiura; Priscila Reina Siliano; Samirah Abreu Gomes; Silvia Regina Silva Moreira; Ita Pfeferman Heilberg
Journal:  Urol Res       Date:  2006-08-04

7.  Dietary management of idiopathic hyperoxaluria and the influence of patient characteristics and compliance.

Authors:  Zeyad R Schwen; Julie M Riley; Yaniv Shilo; Timothy D Averch
Journal:  Urology       Date:  2013-09-17       Impact factor: 2.649

8.  Use of drugs for nephrolithiasis.

Authors:  Martino Marangella; Corrado Vitale; Cristiana Bagnis; Michele Petrarulo; Alberto Tricerri
Journal:  Clin Cases Miner Bone Metab       Date:  2008-05

9.  Temporary risk identification in urolithiasis.

Authors:  Y M Fazil Marickar; Abiya Salim
Journal:  Urol Res       Date:  2009-10-15

Review 10.  Integration and utilization of modern technologies in nephrolithiasis research.

Authors:  Michael S Borofsky; Casey A Dauw; Andrew Cohen; James C Williams; Andrew P Evan; James E Lingeman
Journal:  Nat Rev Urol       Date:  2016-08-23       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.